AG-348 enhances pyruvate kinase activity in red blood cells from patients with pyruvate kinase deficiency

Blood

Volumn 130, Issue 11, 2017, Pages 1347-1356

  Kung, Charles ^a   Hixon, Jeff ^a,c   Kosinski, Penelope A ^a   Cianchetta, Giovanni ^a   Histen, Gavin ^a   Chen, Yue ^a   Hill, Collin ^a,d   Gross, Stefan ^a   Si, Yaguang ^a   Johnson, Kendall ^a   Delabarre, Byron ^a,e   Luo, Zhiyong ^b   Gu, Zhiwei ^b   Yao, Gui ^b   Tang, Huachun ^b   Fang, Cheng ^b   Xu, Yingxia ^b   Lv, Xiaobing ^b   Biller, Scott ^a   Su, Shin San Michael ^a,f   Yang, Hua ^a   Popovici Muller, Janeta ^a,f   Salituro, Francesco ^a,g   Silverman, Lee ^a   Dang, Lenny ^a   more..

^a AGIOS PHARMACEUTICALS   (United States)

^b Shanghai ChemPartner Co Ltd   (China)

^c KSQ THERAPEUTICS   (United States)

^d Precision Medicine Department   (United States)

^e The Consulting Biochemist   (United States)

^f Decibel Therapeutics   (United States)

^g Sage Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIPHOSPHOGLYCERIC ACID; ADENOSINE TRIPHOSPHATE; AG 348; ENZYME ACTIVATOR; N (4 (4 (CYCLOPROPYLMETHYL)PIPERAZINE 1 CARBONYL)PHENYL)QUINAZOLINE 8 SULFONAMIDE; PYRUVATE KINASE; QUINOLONE DERIVATIVE; SULFONAMIDE; UNCLASSIFIED DRUG; AG-348; QUINOLINE DERIVATIVE; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOCHEMICAL ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME DEFICIENCY; ENZYME KINETICS; ERYTHROCYTE; EX VIVO STUDY; GENETIC DISORDER; GLYCOLYSIS; HUMAN; HUMAN CELL; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PYRUVATE KINASE DEFICIENCY; ANIMAL; CHEMISTRY; DEFICIENCY; DISORDERS OF CARBOXYLIC ACID METABOLISM; DONOR; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; HEREDITARY HEMOLYTIC ANEMIA; KINETICS; METABOLISM;

ANEMIA, HEMOLYTIC, CONGENITAL NONSPHEROCYTIC; ANIMALS; ENZYME ACTIVATION; ENZYME ACTIVATORS; ERYTHROCYTES; HUMANS; KINETICS; MICE; PYRUVATE KINASE; PYRUVATE METABOLISM, INBORN ERRORS; QUINOLINES; RECOMBINANT PROTEINS; SULFONAMIDES; TISSUE DONORS;

EID: 85029477346     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-11-753525     Document Type: Article

References (39)

1. Germain D. Apropos of 3 new types of hemolytic anemia in children. Infantile pyknocytosis. Familial hemolytic anemia with erythrocytic inclusions and pigmenturia. Anemia caused by pyruvate-kinase deficiency [in French]. Pediatrie. 1962;17: 323-326.
2. Tanaka KR, Valentine WN, Miwa S. Pyruvate kinase (PK) deficiency hereditary nonspherocytic hemolytic anemia. Blood. 1962;19(3):267-295.
3. Oski FA, Diamond LK. Erythrocyte pyruvate kinase deficiency resulting in congenital nonspherocytic hemolytic anemia. N Engl J Med. 1963;269:763-770.
4. Brunetti P, Puxeddu A, Nenci G, Migliorini E. Haemolytic anaemia due to pyruvate-kinase deficiency. Lancet. 1963;282(7300):169-170.
5. Grace RF, Zanella A, Neufeld EJ, et al. Erythrocyte pyruvate kinase deficiency: 2015 status report. Am J Hematol. 2015;90(9):825-830.
6. Zanella A, Bianchi P. Red cell pyruvate kinase deficiency: from genetics to clinical manifestations. Best Pract Res Clin Haematol. 2000;13(1):57-81.
7. Israelsen WJ, Vander Heiden MG. Pyruvate kinase: function, regulation and role in cancer. Semin Cell Dev Biol. 2015;43:43-51.
8. van Wijk R, van Solinge WW. The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis. Blood. 2005;106(13): 4034-4042.
9. Jurica MS, Mesecar A, Heath PJ, Shi W, Nowak T, Stoddard BL. The allosteric regulation of pyruvate kinase by fructose-1,6-bisphosphate. Structure. 1998;6(2):195-210.
10. Zanella A, Bianchi P, Baronciani L, et al. Molecular characterization of PK-LR gene in pyruvate kinase-deficient Italian patients. Blood. 1997;89(10):3847-3852.
11. Wang C, Chiarelli LR, Bianchi P, et al. Human erythrocyte pyruvate kinase: characterization of the recombinant enzyme and a mutant form (R510Q) causing nonspherocytic hemolytic anemia. Blood. 2001;98(10):3113-3120.
12. Zanella A, Fermo E, Bianchi P, Valentini G. Red cell pyruvate kinase deficiency: molecular and clinical aspects. Br J Haematol. 2005;130(1): 11-25.
13. Garate Z, Quintana-Bustamante O, Crane AM, et al. Generation of a high number of healthy erythroid cells from gene-edited pyruvate kinase deficiency patient-specific induced pluripotent stem cells. Stem Cell Rep. 2015;5(6):1053-1066.
14. Garcia-Gomez M, Calabria A, Garcia-Bravo M, et al. Safe and efficient gene therapy for pyruvate kinase deficiency. Mol Ther. 2016;24(7): 1187-1198.
15. Meza NW, Alonso-Ferrero ME, Navarro S, et al. Rescue of pyruvate kinase deficiency in mice by gene therapy using the human isoenzyme. Mol Ther. 2009;17(12):2000-2009.
16. Staal GE, van Berkel TJ, Nijessen JG, Koster JF. Normalisation of red blood cell pyruvate kinase in pyruvate kinase deficiency by riboflavin treatment. Clin Chim Acta. 1975;60(3):323-327.
17. Blume KG, Arnold H, Hasslinger K, Löhr GW. Effect of riboflavin treatment on human red cell pyruvate kinase deficiency. Clin Chim Acta. 1976; 71(2):331-334.
18. Walsh MJ, Brimacombe KR, Anastasiou D, et al. ML265: a potent PKM2 activator induces tetramerization and reduces tumor formation and size in a mouse xenograft model. In: Probe Reports from the NIH Molecular Libraries Program. Bethesda, MD: National Center for Biotechnology Information; 2010-2013. Available at: http://www.ncbi.nlm.nih.gov/books/NBK153222/. Accessed 24 November 2016.
19. Kung C, Hixon J, Choe S, et al. Small molecule activation of PKM2 in cancer cells induces serine auxotrophy. Chem Biol. 2012;19(9):1187-1198.
20. Valentini G, Chiarelli LR, Fortin R, et al. Structure and function of human erythrocyte pyruvate kinase. Molecular basis of nonspherocytic hemolytic anemia. J Biol Chem. 2002;277(26): 23807-23814.
21. Canu G, De Bonis M, Minucci A, Capoluongo E. Red blood cell PK deficiency: an update of PK-LR gene mutation database. Blood Cells Mol Dis. 2016;57:100-109.
22. Lakomek M, Winkler H, Pekrun A, et al. Erythrocyte pyruvate kinase deficiency. The influence of physiologically important metabolites on the function of normal and defective enzymes. Enzyme Protein. 1994-1995;48(3):149-163.
23. Oski FA, Bowman H. A low Km phosphoenolpyruvate mutant in the Amish with red cell pyruvate kinase deficiency. Br J Haematol. 1969;17(3):289-297.
24. Beutler E. Red Cell Metabolism: A Manual of Biochemical Methods. New York, NY: Grune & Stratton; 1975
25. Bartosz G, Grzelińska E, Wagner J. Aging of the erythrocyte. XIV. ATP content does decrease. Experientia. 1982;38(5):575.
26. Guppy M, Attwood PV, Hansen IA, Sabaratnam R, Frisina J, Whisson ME. pH, temperature and lactate production in human red blood cells: implications for blood storage and glycolytic control. Vox Sang. 1992;62(2):70-75.
27. Nathan DG, Oski FA, Miller DR, Gardner FH. Lifespan and organ sequestration of the red cells in pyruvate kinase deficiency. N Engl J Med. 1968; 278(2):73-81.
28. Mentzer WC Jr, Baehner RL, Schmidt-Schönbein H, Robinson SH, Nathan DG. Selective reticulocyte destruction in erythrocyte pyruvate kinase deficiency. J Clin Invest. 1971;50(3): 688-699.
29. Glader BE. Salicylate-induced injury of pyruvate-kinase-deficient erythrocytes. N Engl J Med. 1976;294(17):916-918.
30. Koller CA, Orringer EP, Parker JC. Quinine protects pyruvate-kinase deficient red cells from dehydration. Am J Hematol. 1979;7(3):193-199.
31. Aizawa S, Kohdera U, Hiramoto M, et al. Ineffective erythropoiesis in the spleen of a patient with pyruvate kinase deficiency. Am J Hematol. 2003;74(1):68-72.
32. Ayi K, Liles WC, Gros P, Kain KC. Adenosine triphosphate depletion of erythrocytes simulates the phenotype associated with pyruvate kinase deficiency and confers protection against Plasmodium falciparum in vitro. J Infect Dis. 2009; 200(8):1289-1299.
33. Bianchi P, Fermo E, Lezon-Geyda K, et al. Molecular characterization of 140 patients in the pyruvate kinase deficiency (PKD) natural history study (NHS): report of 20 new variants. Poster presented at 57th Annual Meeting of the American Society of Hematology. 7 December 2015. Orlando, FL.
34. Giarratana MC, Kobari L, Lapillonne H, et al. Ex vivo generation of fully mature human red blood cells from hematopoietic stem cells. Nat Biotechnol. 2005;23(1):69-74.
35. Grace RF, Rose C, Layton DM, et al. Effects of AG-348, a pyruvate kinase activator, on anemia and hemolysis in patients with pyruvate kinase deficiency: early data from the DRIVE PK study [abstract]. Haematologica. 2016;101(s1). Abstract S466.
36. Park Y, Best CA, Auth T, et al. Metabolic remodeling of the human red blood cell membrane. Proc Natl Acad Sci USA. 2010; 107(4):1289-1294.
37. Weed RI, LaCelle PL, Merrill EW. Metabolic dependence of red cell deformability. J Clin Invest. 1969;48(5):795-809.
38. Khandros E, Thom CS, D’Souza J, Weiss MJ. Integrated protein quality-control pathways regulate free α-globin in murine β-thalassemia. Blood. 2012;119(22):5265-5275.
39. Fersht A. Enzyme Structure and Mechanism. San Francisco, CA: W. H. Freeman; 1977.